Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Medical Benefits: Lycopene (carotenoid/plant pigment) and Selenium (mineral)
Additionally, their under-development triple agonist, Retatrutide, has shown unprecedented weight loss effects in phase 2 clinical trials
GHK-Cu Research Applications Applications are those documented for the 100mg vial, since the compound is the same: copper transport and delivery to copper-dependent enzymes, extracellular matrix biology including collagen and glycosaminoglycan synthesis and matrix metalloproteinase-2 expression, matrikine signalling, and transcriptomic profiling
Toggle Navigation Home About us About us History Products Shop News Contact Links Home You are here: Home
Retatrutide is in Phase 3 clinical trials through Eli Lilly, and cagrilintide is in Phase 3 trials through Novo Nordisk (both as monotherapy and as part of CagriSema)
